Product Pipeline

PTG-100: α4β7 Integrin Specific Oral Peptide Antagonist for IBD

Latest News

September 23, 2015

Protagonist Therapeutics Receives SBIR Funding for Oral IL-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases read more

September 10, 2015

Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer read more

July 16, 2015

Protagonist Therapeutics Raises $40 Million Series C Financing to Advance Oral Peptide Drugs Into Clinical Development read more

Upcoming Events

October 20-21, 2015

BIO Investor Forum
San Francisco, CA

November 2-4, 2015

BioEurope 2015 - 21st Annual International Partnering Conference
Munich, Germany

December 10-12, 2015

2015 Advances in IBD – Crohn’s & Colitis Foundation’s Clinical & Research Conference
Orlando, Florida